345 related articles for article (PubMed ID: 12788977)
21. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.
Amir S; Margaryan NV; Odero-Marah V; Khalkhali-Ellis Z; Hendrix MJ
Cancer Biol Ther; 2005 Apr; 4(4):400-6. PubMed ID: 15846059
[TBL] [Abstract][Full Text] [Related]
22. Maspin. A tumor suppressing serpin.
Sager R; Sheng S; Pemberton P; Hendrix MJ
Adv Exp Med Biol; 1997; 425():77-88. PubMed ID: 9433491
[TBL] [Abstract][Full Text] [Related]
23. Maspin sensitizes breast carcinoma cells to induced apoptosis.
Jiang N; Meng Y; Zhang S; Mensah-Osman E; Sheng S
Oncogene; 2002 Jun; 21(26):4089-98. PubMed ID: 12037665
[TBL] [Abstract][Full Text] [Related]
24. Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer.
Maass N; Hojo T; Zhang M; Sager R; Jonat W; Nagasaki K
Acta Oncol; 2000; 39(8):931-4. PubMed ID: 11206999
[TBL] [Abstract][Full Text] [Related]
25. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation.
Khalkhali-Ellis Z; Hendrix MJ
Cancer Res; 2007 Apr; 67(8):3535-9. PubMed ID: 17440060
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressive maspin and epithelial homeostasis.
Lockett J; Yin S; Li X; Meng Y; Sheng S
J Cell Biochem; 2006 Mar; 97(4):651-60. PubMed ID: 16329135
[TBL] [Abstract][Full Text] [Related]
27. Expression and regulation of tumor suppressor gene maspin in breast cancer.
Maass N; Nagasaki K; Ziebart M; Mundhenke C; Jonat W
Clin Breast Cancer; 2002 Oct; 3(4):281-7. PubMed ID: 12425757
[TBL] [Abstract][Full Text] [Related]
28. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
29. The promise and challenge toward the clinical application of maspin in cancer.
Sheng S
Front Biosci; 2004 Sep; 9():2733-45. PubMed ID: 15353310
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
31. Maspin influences response to doxorubicin by changing the tumor microenvironment organization.
Triulzi T; Ratti M; Tortoreto M; Ghirelli C; Aiello P; Regondi V; Di Modica M; Cominetti D; Carcangiu ML; Moliterni A; Balsari A; Casalini P; Tagliabue E
Int J Cancer; 2014 Jun; 134(12):2789-97. PubMed ID: 24242003
[TBL] [Abstract][Full Text] [Related]
32. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
33. Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
Bernardo MM; Kaplun A; Dzinic SH; Li X; Irish J; Mujagic A; Jakupovic B; Back JB; Van Buren E; Han X; Dean I; Chen YQ; Heath E; Sakr W; Sheng S
Cancer Res; 2015 Sep; 75(18):3970-9. PubMed ID: 26208903
[TBL] [Abstract][Full Text] [Related]
34. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.
Bonfil RD; Chinni S; Fridman R; Kim HR; Cher ML
Urol Oncol; 2007; 25(5):407-11. PubMed ID: 17826661
[TBL] [Abstract][Full Text] [Related]
35. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
36. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
[TBL] [Abstract][Full Text] [Related]
37. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Bagheri-Yarmand R; Mazumdar A; Sahin AA; Kumar R
Int J Cancer; 2006 Jun; 118(11):2703-10. PubMed ID: 16381000
[TBL] [Abstract][Full Text] [Related]
38. Maspin inhibits cell migration in the absence of protease inhibitory activity.
Bass R; Fernández AM; Ellis V
J Biol Chem; 2002 Dec; 277(49):46845-8. PubMed ID: 12384513
[TBL] [Abstract][Full Text] [Related]
39. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Xing RH; Rabbani SA
Endocrinology; 1999 Sep; 140(9):4056-64. PubMed ID: 10465276
[TBL] [Abstract][Full Text] [Related]
40. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features.
Machtens S; Serth J; Bokemeyer C; Bathke W; Minssen A; Kollmannsberger C; Hartmann J; Knüchel R; Kondo M; Jonas U; Kuczyk M
Int J Cancer; 2001 Sep; 95(5):337-42. PubMed ID: 11494236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
